160 related articles for article (PubMed ID: 30520820)
21. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin.
Komuta M; Spee B; Vander Borght S; De Vos R; Verslype C; Aerts R; Yano H; Suzuki T; Matsuda M; Fujii H; Desmet VJ; Kojiro M; Roskams T
Hepatology; 2008 May; 47(5):1544-56. PubMed ID: 18393293
[TBL] [Abstract][Full Text] [Related]
22. Integrated analyses of the genetic and clinicopathological features of cholangiolocarcinoma: cholangiolocarcinoma may be characterized by mismatch-repair deficiency.
Makino K; Ishii T; Takeda H; Saito Y; Fujiwara Y; Fujimoto M; Ito T; Wakama S; Kumagai K; Munekage F; Horie H; Tomofuji K; Oshima Y; Uebayashi EY; Kawai T; Ogiso S; Fukumitsu K; Takai A; Seno H; Hatano E
J Pathol; 2024 May; 263(1):32-46. PubMed ID: 38362598
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.
Akiba J; Nakashima O; Hattori S; Tanikawa K; Takenaka M; Nakayama M; Kondo R; Nomura Y; Koura K; Ueda K; Sanada S; Naito Y; Yamaguchi R; Yano H
Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123
[TBL] [Abstract][Full Text] [Related]
24. Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma.
Yoshino J; Akiyama Y; Shimada S; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Yamaoka S; Tanabe M; Tanaka S
Carcinogenesis; 2020 Jul; 41(6):734-742. PubMed ID: 31665232
[TBL] [Abstract][Full Text] [Related]
25. Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study.
Sasaki M; Sato Y; Nakanuma Y
Virchows Arch; 2024 Mar; ():. PubMed ID: 38532197
[TBL] [Abstract][Full Text] [Related]
26. Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma.
Xu S; Guo Y; Zeng Y; Song Z; Zhu X; Fan N; Zhang Z; Ren G; Zang Y; Rao W
BMC Cancer; 2021 Feb; 21(1):152. PubMed ID: 33579226
[TBL] [Abstract][Full Text] [Related]
27. Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways.
Kongpetch S; Jusakul A; Ong CK; Lim WK; Rozen SG; Tan P; Teh BT
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):233-44. PubMed ID: 25966424
[TBL] [Abstract][Full Text] [Related]
28. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
29. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
[TBL] [Abstract][Full Text] [Related]
30. Histopathological evidence of intrahepatic cholangiocarcinoma occurring in ductal plate malformation: A clinicopathologic study of 5 cases.
Wang Q; Xu Y; Wang SM; Hu AY; Pan YC; Zhang SH
Ann Diagn Pathol; 2021 Dec; 55():151828. PubMed ID: 34571341
[TBL] [Abstract][Full Text] [Related]
31. Genetics of Opisthorchis viverrini-related cholangiocarcinoma.
Jusakul A; Kongpetch S; Teh BT
Curr Opin Gastroenterol; 2015 May; 31(3):258-63. PubMed ID: 25693006
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathologic study on cholangiolocellular carcinoma.
Shiota K; Taguchi J; Nakashima O; Nakashima M; Kojiro M
Oncol Rep; 2001; 8(2):263-8. PubMed ID: 11182037
[TBL] [Abstract][Full Text] [Related]
33. Combined Hepatocellular-Cholangiocarcinoma With Ductal Plate Malformation Pattern: A Case Report With Molecular Analysis.
Moon WS; Song JS; Yu HC; Kim KM; Ahn AR
Int J Surg Pathol; 2024 Feb; 32(1):160-164. PubMed ID: 37128663
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
Lowery MA; Ptashkin R; Jordan E; Berger MF; Zehir A; Capanu M; Kemeny NE; O'Reilly EM; El-Dika I; Jarnagin WR; Harding JJ; D'Angelica MI; Cercek A; Hechtman JF; Solit DB; Schultz N; Hyman DM; Klimstra DS; Saltz LB; Abou-Alfa GK
Clin Cancer Res; 2018 Sep; 24(17):4154-4161. PubMed ID: 29848569
[No Abstract] [Full Text] [Related]
35. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
[TBL] [Abstract][Full Text] [Related]
36. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
[TBL] [Abstract][Full Text] [Related]
37. Intrahepatic cholangiocarcinoma with predominant "ductal plate malformation" pattern: a new subtype.
Nakanuma Y; Sato Y; Ikeda H; Harada K; Kobayashi M; Sano K; Uehara T; Yamamoto M; Ariizumi S; Park YN; Choi JH; Yu E
Am J Surg Pathol; 2012 Nov; 36(11):1629-35. PubMed ID: 23073321
[TBL] [Abstract][Full Text] [Related]
38. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity.
Fujimoto A; Furuta M; Shiraishi Y; Gotoh K; Kawakami Y; Arihiro K; Nakamura T; Ueno M; Ariizumi S; Nguyen HH; Shigemizu D; Abe T; Boroevich KA; Nakano K; Sasaki A; Kitada R; Maejima K; Yamamoto Y; Tanaka H; Shibuya T; Shibata T; Ojima H; Shimada K; Hayami S; Shigekawa Y; Aikata H; Ohdan H; Marubashi S; Yamada T; Kubo M; Hirano S; Ishikawa O; Yamamoto M; Yamaue H; Chayama K; Miyano S; Tsunoda T; Nakagawa H
Nat Commun; 2015 Jan; 6():6120. PubMed ID: 25636086
[TBL] [Abstract][Full Text] [Related]
39. Primary liver carcinoma in genetic hemochromatosis reveals a broad histologic spectrum.
Morcos M; Dubois S; Bralet MP; Belghiti J; Degott C; Terris B
Am J Clin Pathol; 2001 Nov; 116(5):738-43. PubMed ID: 11710692
[TBL] [Abstract][Full Text] [Related]
40. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss.
Misumi K; Hayashi A; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M
Histopathology; 2017 Apr; 70(5):766-774. PubMed ID: 27864835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
